NCT06947967招募中3 期
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter Study of Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype (SWIFT 02)
Chipscreen Biosciences, Ltd.1 个研究点 分布在 1 个国家目标入组 224 人开始时间: 2025年8月12日最近更新:
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 224
- 试验地点
- 1
- 主要终点
- Progression-Free Survival (PFS)
研究概览
简要总结
A Randomised, Double-blind, Multicenter Phase Ⅲ Study to Evaluate the Efficacy and Safety of Tucidinostat versus Placebo in Combination with CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma with Follicular Helper of T Cell Phenotype
详细描述
This is A Randomised, Double-blind, Multicenter Phase Ⅲ Study to Evaluate the Efficacy and Safety of Tucidinostat versus Placebo in Combination with CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma with Follicular Helper of T Cell Phenotype.Participants Will be Randomised (1:1) to ReceiveTucidinostat (Experimental Arm) or Placebo(Control Arm)in Combination with CHOP .
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide written informed consent for the study.
- •Male or female, age ≥ 18 years and ≤80 years.
- •ECOG PS 0,1 or
- •Participants with histologically proven peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH), including: a. angioimmunoblastic T-cell lymphoma, b. follicular helper T-cell lymphoma, follicular type, c. follicular helper T-cell lymphoma, NOS.
- •At least one measurable disease according to the Lugano 2014 Classification.
- •Laboratory criteria are as follows except that caused by lymphoma assessed by the investigator (without receiving any supportive treatment for the following parameters within 2 weeks from the last dose prior to study entry):
- •(1)Hematology values:Hemoglobin (Hb)≥90g/L,Absolute neutrophil count (ANC) ≥1.5×10 9/L, platelets ≥90×10 9/L (2)Biochemical values: Serum creatinine ≤1.5×upper limit of normal(ULN),Total bilirubin ≤1.5 × ULN, Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) ≤2.5×ULN(ALT, AST≦5×ULN if liver involved).
- •7.Expected survival≥6 months.
排除标准
- •Presence of CNS involvement.
- •Received prior therapies targeting lymphoma.
- •Participants planned for autologous or allogeneic transplant as consolidation after CR.
- •Participants with any other malignancy in past 5 years, except for local tumors that have been cured.
- •Prior treatment with cytotoxic drugs for another condition (e.g., rheumatoid arthritis).
- •Any investigational therapy within 3 months.
- •Contraindication to any of the individual components of CHOP.
- •Corticosteroid use > 30 mg/day of prednisone or equivalent, for purposes other than lymphoma symptom control, and the following conditions for inclusion must be met, a. participants receiving corticosteroid treatment with ≤ 30 mg/day of prednisone or equivalent must be documented to be on a stable dose of at least 4 weeks' duration prior to randomization, b. If glucocorticoid treatment is urgently required for lymphoma symptom control prior to the start of study treatment, prednisone 100 mg or equivalent could be given for a maximum of 7 days, but all tumor assessments must be completed prior to start of glucocorticoid treatment.
- •Ongoing serious central nervous system disease or peripheral neuropathy, such as progressive multifocal leukoencephalopathy.
- •Have uncontrolled or significant cardiovascular disease, including a. Grade Ⅱ or higher Congestive heart failure, unstable angina pectoris, myocardial infarction (New York Heart Association Functional Classification ) within 6 months prior to study entry; or arrhythmia requiring treatment, or Left Ventricular Ejection Fraction (LVEF) < 50% during screening stage b.Primary cardiomyopathy (dilated cardiomyopathy, hypertrophic cardiomyocyte, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, et,al) c.History of significant QT interval prolongation, or Corrected QT Interval QTc≥450ms(male), QTc≥470ms（female）at screening d.Symptomatic coronary heart disease requiring treatment e.Any other cardiovascular disease which is inappropriate for the study according to investigators' judgment.
- •History of interstitial lung disease(ILD), or with ongoing signs and symptoms by CT or MRI at the time of screening.
- •Participants with factors that could affect oral medication (such as dysphagia, chronic diarrhea, intestinal obstruction etc), or undergone gastrectomy.
- •History of deep vein thrombosis or pulmonary embolism.
- •History of active bleeding within 2 months prior to the start of Cycle 1;or participants receiving anticoagulation therapy; or participants with evidence of bleeding potential according to investigators' judgment ( esophageal varices, active ulcer, or fecal occult blood test positive etc. ). participants with bleeding led by lymphoma according to investigators' judgment are eligible.
- •Major surgical procedures (craniotomy, thoracotomy, or laparotomy) or severe unhealed wounds, ulcers, or fractures were performed within 4 weeks. Tissue biopsy or other minor surgical procedure (other than venipuncture for intravenous fluids) within 7 days.
- •Active infection requiring systemic treatment (oral, intravenous infusion) was present within 2 weeks prior to the first dose. Participants receiving prophylactic antibiotic therapy (e.g., interstitial pneumonia) may be enrolled.
- •HBsAg or HBcAb positive with virus replication (except for virus replication positive that non-active hepatitis B assessed by investigators), HCV-Ab positive with virus replication positive, active syphilis infection (positive for syphilitic-specific and non-specific antibodies).
- •History of HIV infection, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation or stem cell transplantation.
- •Any mental or cognitive disorder, that would impair the ability to understand the informed consent document, or limit compliance with study requirements/ treatment.
- •Drug or alcohol abuse.
- •Women patients of childbearing potential who are unwilling or unable to use an effective method of contraception throughout the treatment period of this trial and for 12 weeks after the last dose of tucidinostat/placebo or CHOP, whichever is the latest, or the spouses of male participants.
- •Any other condition which is inappropriate for the study according to investigators' judgment.
研究组 & 干预措施
C-CHOP
Experimental
干预措施: CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone) (Drug)
C-CHOP
Experimental
干预措施: Tucidinostat (Drug)
CHOP
Placebo Comparator
干预措施: CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone) (Drug)
CHOP
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Progression-Free Survival (PFS)
时间窗: Up to approximately 60 month
Defined as the duration from the date of randomization to the date of progression, relapse from CR, or death, whichever occurred first.
次要结局
- Complete Response Rate(CRR)(Up to approximately 36 months)
- Overall response rate (ORR)(Up to approximately 36months)
- Event Free Survival (EFS)(Up to approximately 60 month)
- Disease-Free Survival (DFS)(Up to approximately 60 month)
- Overall Survival (OS)(Up to approximately 60 month)
- Safety and Tolerability(Up to approximately 78 months)
- Plasma concentrations of tucidinostat(Up to approximately 60 month)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)Triple Negative Breast CancerNCT02425891Hoffmann-La Roche902
进行中（未招募）
3 期
A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye DropsMyopiaNCT06209320Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.777
已完成
3 期
Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart FailureChronic Systolic Heart FailureNCT04468529Zensun Sci. & Tech. Co., Ltd.154
已完成
3 期
Safety & Efficacy Study of MRX-7EAT Patch in the Treatment of Pain of the ShoulderTendonitisShoulder PainBursitisNCT01506154MEDRx USA, Inc.210
已完成
3 期
MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the ShoulderAcute TendonitisBursitisNCT01161615MEDRx USA, Inc.350